PET scan for HER2 breast cancer during treatment
Part of Cancer, Skin clinical trials.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and in good enough health to be active (ECOG 0 or 1).
- Your breast cancer is HER2-positive or HER2-low.
- You are currently receiving treatment before surgery (neoadjuvant therapy).
- Your heart, bone marrow, kidneys, liver, and blood clotting are working well.
- Your doctor expects you to live longer than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This early study tests a special PET scan (a type of imaging) to look at newly diagnosed ER-positive breast cancer. The goal is to see how well the scan can detect and measure cancer, which may help guide care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.